Clarus Therapeutics Holdings Receivables

Clarus Therapeutics Holdings posts a receivables of $8.7M as of June 2022. That compares with $6.2M in the prior-year period — up 39.7% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Clarus Therapeutics Holdings's receivables was $6.2M. The latest reading is $8.7M — a 39.7% year-over-year increase (period ending June 2022). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Clarus Therapeutics Holdings's financial statement story. At $8.7M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CRXT's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Clarus Therapeutics Holdings's other metric pages and overview cover the third.